Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREATHE
NCT07323732Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2026
- Primary completion
- Jan 2029
- Modality
- Nanoparticles, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of BIO 300 in pneumonitis, sponsored by Memorial Sloan Kettering Cancer Center. Started Jan 2026; status: recruiting.
02
Drugs
BIO 300
03
Conditions
pneumonitis
Beyond the preview
Go deeper on NCT07323732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07323732.